Newsletter Life Sciences Voice Top Five Newsletter

Life Sciences Voice Top Five Newsletter


In the latest edition of the Life Sciences Voice Top Five Newsletter we delve into the fourth episode of the leading minds podcast with medtech industry expert Amar Sawhney, we also take a look at Eli Lilly’s obesity drug showing promise, GSK’s HIV drug making it to the European market, and other top news!

Leading Minds Podcast with MedTech Veteran Amar Sawhney 

In our latest podcast, we had the privilege of hearing from Amar Sawhney, a prominent figure in the healthcare industry and co-founder of successful biotech companies. Sawhney shares his profound insights on achieving unprecedented growth and success by establishing a solid foundation rooted in meaningful science, strong values, and a clear purpose. He highlights the power of blending cutting-edge scientific innovation with ethical principles and a deeper sense of purpose to drive exceptional achievements in the healthcare sector. Aspiring entrepreneurs and industry leaders seeking to make a positive impact in life sciences will find his guidance invaluable.

Eli Lilly’s Obesity Drug Shows Promising Results in Late-Stage Studies

Exciting news in the fight against obesity! Eli Lilly’s investigational drug, tirzepatide, has shown promising outcomes in two late-stage clinical trials. Among participants with type 2 diabetes and obesity, the drug led to significant reductions in body weight and blood sugar levels. These encouraging results offer hope for those struggling with obesity-related conditions, potentially introducing a much-needed effective treatment option to address this global health concern.

GSK’s HIV Prevention Drug Advances Towards European Marketing Approval

A major breakthrough in HIV prevention is on the horizon! GlaxoSmithKline’s long-acting injectable drug, cabotegravir, has received a recommendation for approval from the European Medicines Agency (EMA). The recommendation follows successful clinical trials involving at-risk populations. If approved, cabotegravir will be a vital addition to existing HIV prevention strategies, providing a convenient and discreet option for individuals seeking protection against HIV infection.

FDA Greenlights Tarsus Xydemvy, a Groundbreaking Eyelid Condition Treatment

In a significant development for eye health, the FDA has granted approval for Tarsus Pharmaceuticals’ Xydemvy, the world’s first treatment for Demodex blepharitis. This chronic inflammatory eye condition affects numerous individuals worldwide, causing discomfort and vision issues. The approval of Xydemvy marks a crucial milestone in addressing this unmet medical need, offering a promising treatment option to alleviate symptoms and enhance patients’ quality of life.

Glucotracks CGM Implant Proves Feasibility in Initial Study

Innovations in diabetes management are making strides! Glucotracks’ continuous glucose monitoring (CGM) implant has successfully passed its first feasibility study. This revolutionary implantable device aims to transform glucose monitoring for individuals with diabetes, providing continuous and real-time data without the need for frequent finger pricking. The positive outcomes from the initial study are a promising step towards advancing this technology, potentially offering patients a more convenient and accurate way to monitor their glucose levels.
Exclusive Sponsor: Axtria – the leading global provider of cloud software and data analytics solutions to the life sciences industry.

Latest news

Life Sciences Voice Top Five Newsletter

Welcome to the latest edition of the Life Sciences Voice Top Five Newsletter, your source for the top developments...

Pfizer’s Phase 3 Trial for Gene Therapy in Boys with Duchenne Muscular Dystrophy Fails to Show Functional Improvement

Pfizer's gene therapy for Duchenne muscular dystrophy failed to improve motor function in young boys in a key late-stage...

Phase 3 Trial Results for Loqtorzi Show Positive Results in Advanced Hepatocellular Carcinoma Patients

Phase 3 trial results for Loqtorzi (toripalimab) and Avastin (bevacizumab) show that in first-line patients suffering from advanced hepatocellular...

Must read

Surrounded by controversy, FDA approves Biogen’s Alzheimer’s drug Aduhelm

In the middle of the debate about the Alzheimer’s drug approval, the United States FDA has authorized Aduhelm

You might also likeRELATED
Recommended to you